|
EP3696822A1
|
|
Means and methods for determining a personalized cutoff value for a biomarker
|
|
JP2019039915A
|
|
Means and methods for assessing quality of biological sample
|
|
EP3502703A1
|
|
Method for the assessment of nafld
|
|
EP3502699A1
|
|
Methods for diagnosing pancreatic cancer
|
|
US2017176477A1
|
|
Means and methods to diagnose liver toxicity using putrescine as biomarker
|
|
AU2016282362A1
|
|
Means and methods for diagnosing pancreatic cancer in a subject based on a biomarker panel
|
|
CA2954863A1
|
|
Means and methods for assessing a quality of a biological sample
|
|
EP3123174A1
|
|
Means and methods for determination of quality of blood samples based on metabolite panel
|
|
US2016313338A1
|
|
Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel
|
|
WO2014125443A1
|
|
Means and methods for assessing the quality of a biological sample
|
|
EP2904397A1
|
|
Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
|
|
US2015204851A1
|
|
Methods for identifying diabetes drugs
|
|
EP3486657A2
|
|
Means and methods for diagnosing pancreatic cancer in a subject
|
|
WO2012164026A1
|
|
Methods for diagnosing multiple sclerosis
|
|
WO2012085890A1
|
|
Means and method for predicting diabetes
|
|
CA2799032A1
|
|
Methods to diagnose liver diseases
|
|
KR20130119335A
|
|
Means and methods for diagnosing pancreatic cancer in a subject
|
|
WO2011067243A1
|
|
Means and methods for diagnosing multiple sclerosis
|
|
WO2010139711A1
|
|
Means and methods for diagnosing prostate carcinomas
|
|
US2011113863A1
|
|
Means and methods diagnosing gastric bypass and conditions related thereto
|
